Orlistat and application of combination of orlistat and gemcitabine in preparation of medicine for treating pancreatic cancer

The invention discloses application of orlistat in preparation of a medicine for treating pancreatic cancer, and belongs to the technical field of biological medicine. Orlistat is combined with pancreatic cancer cell 3-hydroxyacyl coenzyme A dehydratase 2 (HACD2) target protein, has the activity of inhibiting pancreatic cancer cell proliferation, can inhibit pancreatic cancer cell PANC-1 and AsPC-1 proliferation and tumor growth, and is combined with gemcitabine to obtain orlistat capable of enhancing the pancreatic cancer treatment effect of gemcitabine; orlistat and drug combination of orlistat and gemcitabine have a good application prospect in clinical treatment of pancreatic cancer. 本发明公开了奥利司他在制备治疗胰腺癌药物中的应用，属于生物医药技术领域；所述奥利司他与胰腺癌细胞3-羟基酰辅酶A脱水酶2（HACD2）靶蛋白结合，具有抑制胰腺癌细胞增殖的活性，奥利司他能抑制胰腺癌细胞PANC-1、AsPC-1的增殖及肿瘤生长，并且联合吉西他滨得到奥利司他能增强吉西他滨治疗胰腺癌的效果；奥利司他及其与吉西他滨联合用药在临床胰腺癌的治疗中有良好的应用前景。